A Randomized Trial of AmBisome Monotherapy and Combination of AmBisome and Miltefosine for the Treatment of Visceral Leishmaniasis in HIV-Positive Patients in India
Sakib Burza(Unknown), Pradeep Das(Rajendra Memorial Research Institute of Medical Sciences), Neâl Alexander(University of London), Amit Harshana, Krishna Pandey(Rajendra Memorial Research Institute of Medical Sciences), Laura Moretó‐Planas, Fabiana Alves(Drugs for Neglected Diseases Initiative), Deepak Kumar(All India Institute of Medical Sciences Jodhpur), Chandra Shekhar Lal(Rajendra Memorial Research Institute of Medical Sciences), Vidya Nand Rabi Das(Rajendra Memorial Research Institute of Medical Sciences), Vishal Goyal(Chandigarh University), Neena Verma(Rajendra Memorial Research Institute of Medical Sciences), Shahwar Kazmi(University of Karachi), Estrella Lasry(Médecins Sans Frontières), Suman Rijal(Nepal Cancer Hospital and Research Center), Raman Mahajan
Cited by 1
Related Papers
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
|Nature Human Behaviour|2020|445
α <sup>+</sup> -Thalassemia protects children against disease caused by other infections as well as malaria
|Proceedings of the National Academy of Sciences|1997|302
Role of flies and provision of latrines in trachoma control: cluster-randomised controlled trial
|The Lancet|2004|239
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives
|Clinical Microbiology Reviews|2018|218
Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
|PLoS neglected tropical diseases|2017|78